Valneva SE (NAS:VALN)
$ 4.225 0 (0%) Market Cap: 342.99 Mil Enterprise Value: 390.44 Mil PE Ratio: 0 PB Ratio: 1.40 GF Score: 70/100

Full Year 2021 Valneva SE Earnings Call Transcript

Mar 24, 2022 / 02:00PM GMT
Release Date Price: $38.15 (+0.74%)
Operator

Good day, and thank you for standing by. Welcome to the Valneva Presents its Audited Full Year 2021 Financial Results Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to our first speaker today, Thomas Lingelbach. Please go ahead.

Thomas Lingelbach
Valneva SE - Chairman of the Management Board, President & CEO

Welcome, and good day to our quarter 1 analyst call where we will report our full year 2021 results and provide corporate updates. So if you move to the Slide 2, please and acknowledge the disclaimer.

We go on to Slide 4 of the presentation. Yes, 2021 has been an exceptional year for Valneva. And we have been able to make excellent progress in all of our clinical programs. For Lyme disease, we reported further positive Phase II results, including booster data. We determined finally the final Phase III dose and vaccination schedule.

For our COVID-19 vaccine, we reported positive Phase III results, obtained a first emergency

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot